VCBeat Health Contact Us
Home Innovent Bio (01801.HK) Surges Over 4% as IBI3031 Enters Phase I Trial, Pioneering Precision Therapy for Thyroid Eye Disease

Innovent Bio (01801.HK) Surges Over 4% as IBI3031 Enters Phase I Trial, Pioneering Precision Therapy for Thyroid Eye Disease

May 21, 2026 14:54 CST Updated 15:47
Innovent

High-end Biologics Developer